{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:45:43Z","timestamp":1787021143045,"version":"build-2736575974"},"reference-count":8,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2009,1,1]]},"DOI":"10.1200\/jco.2008.20.3737","type":"journal-article","created":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T23:04:01Z","timestamp":1228172641000},"page":"156-157","source":"Crossref","is-referenced-by-count":30,"title":["Erythema Multiforme\/Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis in Lenalidomide-Treated Patients"],"prefix":"10.1200","volume":"27","author":[{"given":"Carmen P.","family":"Castaneda","sequence":"first","affiliation":[{"name":"Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy A.","family":"Brandenburg","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bwire","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham H.","family":"Burton","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome B.","family":"Zeldis","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Letko GN, Papaliodis DN, Papaliodis GN, et al: Stevens-Johnson syndrome and toxic epidermal necrolysis: A review of the literature. Annals Allergy Asthma Immunol 94:419,2007-436,","DOI":"10.1016\/S1081-1206(10)61112-X"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1997.tb02524.x"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332404"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701033"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf350"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3696"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1159\/000102604"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Svigguni H, Davis M, Rajkumar V, et al: Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 142:1298,2006-1302,","DOI":"10.1001\/archderm.142.10.1298"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.20.3737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:23:49Z","timestamp":1653510229000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.20.3737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,1]]}},"alternative-id":["10.1200\/JCO.2008.20.3737"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.20.3737","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}